

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Apixaban for the prevention of venous thromboembolism

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equality issues were raised during draft scope consultation. Consultees raised the issue of providing non-injectable medications for people with needle phobia. Dabigatran and rivaroxaban (both oral agents) are currently recommended by NICE as options for prevention of VTE in elective knee and hip surgery.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equality issues were raised in any of the submission made during the course of the appraisal.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Not applicable as the Committee recommended that a Final appraisal document be produced.

**Approved by Associate Director (name):** Janet Robertson

**Date:** 17/11/11

**Final appraisal determination**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

Not applicable

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?
Not applicable

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
No equality issues were identified by the Committee and this has been stated in the 'Summary of Appraisal Committee's key conclusions' in the final appraisal document.

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 23/1/12